A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.

This study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of danuglipron (PF-06882961)-a novel, oral, small-molecule glucagon-like peptide-1 receptor agonist-in Japanese participants with type 2 diabetes mellitus (T2DM).